News - Dermatologicals, Bayer


Current filters:


Popular Filters

Bayer’s Diane-35 back on French market

Bayer’s Diane-35 back on French market


Following the confirmation of the positive benefit-risk profile by the European Medicines Agency, German…

BayerDermatologicalsDiane-35EuropeFranceMarkets & MarketingPharmaceutical

KYTHERA submental fat drug candidate meets all primary endpoints in Ph III


US biotech firm KYTHERA Biopharmaceuticals (Nasdaq: KYTH) saw its stock upgraded to $50 a share from…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

Benefits of Diane 35 and generics outweigh risks in specific patient group, says EMA unit; other actions


The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that…


Significant and sustainable reduction in "double chin" with Bayer's ATX-101


German drug major Bayer's (BAYN: DE) investigational drug ATX-101 can significantly and sustainably reduce…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

Positive results for KYTHERA and Bayer's ATX-101 in the reduction of "double chin"


Privately-held US biotech firm KYTHERA Biopharmaceuticals announced positive interim results from a Phase…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

French medicines regulator takes Bayer acne drug Diane-35 off market


Following a recent investigation (The Pharma Letter January 29), the French medicines agency (ANSM) announced…

BayerDermatologicalsDiane-35EuropePharmaceuticalReproductiveWomen's Health

EMA to review third- and fourth-generation combined OCs; France investigates Diane-35


The European Medicines Agency has been asked by France to review third- and fourth-generation combined…

BayerDermatologicalsDiane-35EuropePharmaceuticalRegulationReproductiveWomen's Health

Back to top